Pharmaceutical Business review

BioMarin Q4 net income increases

Net income for the year ended December 31, 2008 was $30.8 million, or $0.29 per fully diluted share, compared to a net loss of $15.8 million, or $0.16 per fully diluted share, for the year ended December 31, 2007.

For the fourth quarter of 2008, the company reported net revenue of $99.3 million, compared to $44.9 million for the corresponding period of 2007. For the year ended December 31, 2008, the company posted net revenue of $296.5 million, compared to $121.6 million for the year ended December 31, 2007.

Jean-Jacques Bienaime, CEO of BioMarin, said: “We achieved our first profitable full year in 2008, with an increase of 144% in total revenue over 2007 driven by our three growing commercial products. We ended the year with a strong cash position and a promising development pipeline.”